ABT vs CRAI · P/E 25, rev $44.33B vs P/E 20, rev $411.8M
Abbott Laboratories (ABT) versus CRA International Inc (CRAI) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
CRA International Inc (CRAI) is a consulting services company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported CRAI revenue for 2026-07-04 was $411.8M. Net income was $24.6M. CRAI currently screens at market cap $952.1M and trailing P/E 20.4.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. CRAI currently screens at market cap $952.1M and trailing P/E 20.4.
Not investment advice. Open the ABT and CRAI stock pages for the full models.
Not investment advice.